Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;7(2):30-4.

Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients

Affiliations

Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients

Mozaffar Aznab et al. Int J Hematol Oncol Stem Cell Res. 2013.

Abstract

Myelodysplastic syndrome is a bone marrow failure in which differentiation and maturity do not happen naturally and dysplasia exists in each of 3 cell categories in Bone marrow. Refractory anemia is one of the major complaints with which the patients come to hematology clinics, which in diagnostic considerations lead to MDS as diagnosis. Often there is no recognized reason for this, so it is called "primary MDS". In practice, we meet some patients who have MDS criteria however we can also find specific reasons for it; therefore we call it "secondary MDS". One of the most important reasons for secondary MDS is the side effects of medications used in chemotherapy and radiotherapy in patients who undergo these therapies. We observed 6 patients in this case study during lengthy follow up that were diagnosed as MDS and during follow up period malignancy appeared in 6 cases. Supportive and therapeutic measures in these patients did not considerably improve blood cell count, most patients required blood injection and antibiotics for infection treatment. However align with malignancy treatment such problems are completely resolved both in terms of clinical and laboratory.

Keywords: Malignancy; Myelodysplastic syndrome; Paraneoplastic syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients was a 27 year old female Dyserythropoiesis, Dysgranolopoiesis (pseudo pelger huet raw)
Figure 2A
Figure 2A
A 49 year old man with dysmegakaryopoiesis Unilobule megakaryocytic
Figure 2B
Figure 2B
49 year old man who was referred to clinic because of Macrocytic Anemia Dyserythropoiesis, Dysgranolopoiesis
Figure 3
Figure 3
The third patient was a 40 year old female Dyserythropoiesis
Figure 4
Figure 4
A 28 year old female Dyserythropoiesis
Figure 5
Figure 5
39 year old female

Similar articles

References

    1. Greenberg PL. The smoldering myeloid leukemia states: clinical and biologic features. Blood. 1983;61:1035–1044. - PubMed
    1. Koeffler HP, Golde DW. Human preleukemia. Ann Intern Med. 1980;93:347–353. - PubMed
    1. Noel P, Solberg LA., Jr Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol. 1992;12:193–215. - PubMed
    1. Doll DC, List AF. Myelodysplastic syndromes. West J Med. 1989;151:161–167. - PMC - PubMed
    1. Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994;87:743–745. - PubMed

LinkOut - more resources